Lyra Therapeutics, Inc.
LYRA
$4.19
$0.184.49%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 600.00K | 770.00K | 1.19M | 1.53M | 1.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 600.00K | 770.00K | 1.19M | 1.53M | 1.47M |
| Cost of Revenue | 20.40M | 22.25M | 30.40M | 43.77M | 49.67M |
| Gross Profit | -19.80M | -21.48M | -29.22M | -42.23M | -48.20M |
| SG&A Expenses | 12.61M | 14.31M | 15.95M | 18.50M | 19.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.01M | 36.56M | 46.35M | 62.27M | 68.92M |
| Operating Income | -32.41M | -35.79M | -45.17M | -60.73M | -67.44M |
| Income Before Tax | -32.93M | -38.82M | -79.50M | -93.40M | -97.56M |
| Income Tax Expenses | 15.00K | 19.00K | 29.00K | 39.00K | 50.00K |
| Earnings from Continuing Operations | -32.95 | -38.84 | -79.53 | -93.44 | -97.61 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.95M | -38.84M | -79.53M | -93.44M | -97.61M |
| EBIT | -32.41M | -35.79M | -45.17M | -60.73M | -67.44M |
| EBITDA | -31.90M | -35.34M | -44.70M | -60.26M | -67.04M |
| EPS Basic | -23.78 | -29.46 | -60.71 | -71.75 | -75.69 |
| Normalized Basic EPS | -13.93 | -16.13 | -20.51 | -27.82 | -31.06 |
| EPS Diluted | -23.78 | -29.46 | -60.71 | -71.75 | -75.69 |
| Normalized Diluted EPS | -13.93 | -16.13 | -20.51 | -27.82 | -31.06 |
| Average Basic Shares Outstanding | 5.74M | 5.28M | 5.24M | 5.21M | 5.13M |
| Average Diluted Shares Outstanding | 5.74M | 5.28M | 5.24M | 5.21M | 5.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |